Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

Guyatt "GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables" J Clin Epidemiol (2011) 10.1016/j.jclinepi.2010.04.026

[4]

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

Jeff Andrews, Gordon Guyatt, Andrew D. Oxman et al.

Journal of Clinical Epidemiology 2013 10.1016/j.jclinepi.2012.03.013

[5]

Magiorakos "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance" Clin Microbiol Infect (2012) 10.1111/j.1469-0691.2011.03570.x

[6]

Kadri "Difficult-to-Treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents" Clin Infect Dis (2018) 10.1093/cid/ciy378

[7]

Taiwan C.D.C. Taiwan Nosocomial Infections Surveillance System (TNIS) 20092009; Taiwan Centers for Disease Control(https://www.cdc.gov.tw/En/File/Get/v6rNFa_LQPGg0qOffOYbhw (Access Date Access 2009, date last accessed).

[8]

Taiwan C.D.C. Taiwan Healthcare associated infections and Antimicrobial resistance Surveillance (THAS)(previously known as Taiwan Nosocomial Infections Surveillance System TNIS) 20202020; Taiwan Centers for Disease Control(https://www.cdc.gov.tw/En/File/Get/rQPhOnWeQkOXljor7MUrvA (Access Date Access 2020, date last accessed).

[9]

Weiner-Lastinger "Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017" Infect Control Hosp Epidemiol (2020) 10.1017/ice.2019.296

[10]

Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States

Hilmar Wisplinghoff, Tobias Paulus, Marianne Lugenheim et al.

Journal of Infection 2012 10.1016/j.jinf.2011.12.008

[11]

Karakonstantis "Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems" Infection (2020) 10.1007/s15010-020-01520-6

[12]

Isler "New treatment options against carbapenem-resistant Acinetobacter baumannii infections" Antimicrob Agents Chemother (2019) 10.1128/aac.01110-18

[13]

Du "Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis" Am J Infect Control (2019) 10.1016/j.ajic.2019.03.003

[14]

Betrosian "High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii" Scand J Infect Dis (2007) 10.1080/00365540600951184

[15]

Aydemir "Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia" Epidemiol Infect (2013) 10.1017/s095026881200194x

[16]

Qin "Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii" Int J Clin Pharmacol Therapeut (2018) 10.5414/cp203102

[17]

Shields "Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients" PLoS One (2012) 10.1371/journal.pone.0052349

[18]

Garnacho-Montero "Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii" Chemotherapy (2013) 10.1159/000356004

[19]

Khawcharoenporn "Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia" Int J Antimicrob Agents (2014) 10.1016/j.ijantimicag.2014.01.016

[20]

Zalts "Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin–sulbactam" Am J Therapeut (2016) 10.1097/mjt.0b013e3182a32df3

[21]

Ye "Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex" BMC Infect Dis (2016) 10.1186/s12879-016-1717-6

[22]

Liang "Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii" Clin Microbiol Infect (2018) 10.1016/j.cmi.2017.10.033

[23]

Jean "Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium?" Medicine (Baltim) (2018) 10.1097/md.0000000000012278

[24]

Hsieh "Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization" J Microbiol Immunol Infect (2016) 10.1016/j.jmii.2014.08.009

[25]

Tsioutis "Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients" Int J Antimicrob Agents (2016) 10.1016/j.ijantimicag.2016.07.007

[26]

Chuang "Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis" BMC Infect Dis (2014) 10.1186/1471-2334-14-102

[27]

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

Jason M Pogue, Keith S Kaye, Michael P Veve et al.

Clinical Infectious Diseases 2019 10.1093/cid/ciz816

[28]

van Duin "Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae" Clin Infect Dis (2018) 10.1093/cid/cix783

[29]

Leu "Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii" J Microbiol Immunol Infect (2014) 10.1016/j.jmii.2013.05.007

[30]

Zusman "Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems" Antimicrob Agents Chemother (2013) 10.1128/aac.01230-13

[31]

Bian "Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic/pharmacodynamic model" Antimicrob Agents Chemother (2019) 10.1128/aac.01989-18

[32]

Fan "Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model" PLoS One (2016) 10.1371/journal.pone.0157757

[33]

Hsieh "Association of capsular types with carbapenem resistance, disease severity, and mortality in Acinetobacter baumannii" Emerg Microb Infect (2020) 10.1080/22221751.2020.1822757

[34]

Kengkla "Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis" J Antimicrob Chemother (2018) 10.1093/jac/dkx368

[35]

Vardakas "Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis" Int J Antimicrob Agents (2018) 10.1016/j.ijantimicag.2017.05.016

[36]

Korbila "Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study" Clin Microbiol Infect (2010) 10.1111/j.1469-0691.2009.03040.x

[37]

Feng "Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study" Clin Microbiol Infect (2021) 10.1016/j.cmi.2021.01.020

[38]

Zheng "Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex" J Microbiol Immunol Infect (2020) 10.1016/j.jmii.2019.08.007

[39]

Lashinsky "Minocycline for the treatment of multidrug and extensively drug-resistant A. Baumannii: a review" Infect Dis Ther (2017) 10.1007/s40121-017-0153-2

[40]

Li "The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates" J Chemother (2020) 10.1080/1120009x.2020.1764282

[41]

Jiang "Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis" Infect Drug Resist (2018) 10.2147/idr.s172137

[42]

Nutman "Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes" Clin Microbiol Infect (2020) 10.1016/j.cmi.2020.03.035

[43]

Batirel "Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections" Eur J Clin Microbiol Infect Dis (2014) 10.1007/s10096-014-2070-6

[44]

Park "Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem" J Int Med Res (2019) 10.1177/0300060519879336

[45]

Katip "A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis" Antibiotics (2020) 10.3390/antibiotics9100647

[46]

Dickstein "Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup Analysis of a randomized clinical trial" Clin Infect Dis (2019) 10.1093/cid/ciy988

[47]

Paul "Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial" Lancet Infect Dis (2018) 10.1016/s1473-3099(18)30099-9

[48]

Zilberberg "Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study" Crit Care (2014) 10.1186/s13054-014-0596-8

[49]

Cai "Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa" Open Forum Infect Dis (2017) 10.1093/ofid/ofx176

[50]

Shortridge "Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 Years from the SENTRY antimicrobial surveillance program, 1997-2016" Open Forum Infect Dis (2019) 10.1093/ofid/ofy343

Showing 50 of 197 references

Cited By

85

Multidrug-resistant Gram-negative bacterial infections

Nenad Macesic, Anne-Catrin Uhlemann · 2025

The Lancet

Metrics

85

Citations

197

References

Details

Published: Jun 01, 2022
Vol/Issue: 55(3)
Pages: 359-386
License: View

Authors

Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan

Funding

Medical Foundation

Cite This Article

Cheng Len Sy, Pao-Yu Chen, Chun-Wen Cheng, et al. (2022). Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. Journal of Microbiology, Immunology and Infection, 55(3), 359-386. https://doi.org/10.1016/j.jmii.2022.02.001

Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

You May Also Like